GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cullinan Therapeutics Inc (NAS:CGEM) » Definitions » Accumulated Depreciation

Cullinan Therapeutics (Cullinan Therapeutics) Accumulated Depreciation : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Cullinan Therapeutics Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Cullinan Therapeutics's quarterly accumulated depreciation increased from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($-0.35 Mil) but then stayed the same from Dec. 2023 ($-0.35 Mil) to Mar. 2024 ($0.00 Mil).

Cullinan Therapeutics's annual accumulated depreciation declined from Dec. 2021 ($-0.23 Mil) to Dec. 2022 ($-0.14 Mil) but then increased from Dec. 2022 ($-0.14 Mil) to Dec. 2023 ($-0.35 Mil).


Cullinan Therapeutics Accumulated Depreciation Historical Data

The historical data trend for Cullinan Therapeutics's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cullinan Therapeutics Accumulated Depreciation Chart

Cullinan Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accumulated Depreciation
Get a 7-Day Free Trial -0.12 -0.18 -0.23 -0.14 -0.35

Cullinan Therapeutics Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -0.35 -

Cullinan Therapeutics Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.


Cullinan Therapeutics Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Cullinan Therapeutics's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.


Cullinan Therapeutics (Cullinan Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
One Main Street, Suite 520, Cambridge, MA, USA, 02142
Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.
Executives
Nadim Ahmed director, officer: President and CEO C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Jacquelyn L Sumer officer: Chief Legal Officer C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Jeffrey Alan Jones officer: Chief Medical Officer ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Jennifer Michaelson officer: See Remarks C/O CULLINAN MANAGEMENT, INC., ONE MAIN STREET SUITE 520, CAMBRIDGE MA 02142
Jeffrey Trigilio officer: Chief Financial Officer C/O CULLINAN MANAGEMENT, INC., ONE MAIN STREET, SUTIE 520, CAMBRIDGE MA 02142
David P. Ryan director C/O CULLINAN ONCOLOGY, INC., ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Vision Scs F2 10 percent owner 74 GRAND RUE, LUXEMBURG N4 L-1660
Savill Corrine officer: Acting Chief Business Officer C/O CULLINAN ONCOLOGY, LLC, ONE MAIN STREET SUITE 520, CAMBRIDGE MA 02142
F2 Bioscience I 2017 Ltd 10 percent owner 8, RUE SAINT-LEGER, GENEVA V8 CH 1205
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Anne-marie Martin director ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104